Category: Arboviruses Unit

Posted on

Papers – Dengue & Arbovirosis

2018

An overview of mosquito vectors of Zika virus.
Boyer S, Calvez E, Chouin-Carneiro T, Diallo D, Failloux AB.
Microbes Infect. 2018 Mar 2. pii: S1286-4579(18)30039-X. doi: 10.1016/j.micinf.2018.01.006. 

2017

Dengue-1 virus and vector competence of Aedes aegypti (Diptera: Culicidae) populations from New Caledonia.
Calvez E, Guillaumot L, Girault D, Richard V, O’Connor O, Paoaafaite T, Teurlai M, Pocquet N, Cao-Lormeau VM, Dupont-Rouzeyrol M.
Parasit Vectors. 2017 Aug 9;10(1):381. doi: 10.1186/s13071-017-2319-x.

A neutralization assay for Zika and Dengue viruses using a real-time PCR-based endpoint assessment
Wilson HL, Tran T, Druce J, Dupont-Rouzeyrol M, Catton M.
J Clin Microbiol. 2017 pii: JCM.00673-17. doi: 10.1128/JCM.00673-17.

Socioeconomic and environmental determinants of dengue transmission in an urban setting: an ecological study in Nouméa, New Caledonia.
Zellweger M, Cano J,  Mangeas M, Taglioni F, Mercier A, Despinoy M, Menkès C, Dupont-Rouzeyrol M, Nikolay B and Teurlai M. 
PLoS Negl Trop Dis. 2017 11(4):e0005471.

Zika virus infection and myasthenia gravis: Report of 2 cases.
Molko N, Simon O, Guyon D, Biron A, Dupont-Rouzeyrol M, Gourinat AC.
Neurology. 2017 Feb 10. pii: 10.1212

2016

Vertical Transmission of Dengue Virus in the Peripartum Period and Viral Kinetics in Newborns and Breast Milk: New Data.
Arragain L*, Dupont-Rouzeyrol M*, O’Connor O, Sigur N, Grangeon JP, Huguon E, Dechanet C, Cazorla C, Gourinat AC, Descloux E.
J Pediatric Infect Dis Soc. 2016. pii: piw058.

Global spread of chikungunya virus a lesson for Aedes-transmitted arboviruses.
Duarte dos Santos C, Dupont-Rouzeyrol M, Sam IC, Roques P. CAB
Reviews. 2016 11(18):1-12.

 Zika virus infection as an unexpected finding in a Leptospirosis patient.
Biron A, Cazorla C, Amar J, Pfannstiel A, Dupont-Rouzeyrol M, Goarant C.
JMM Case Rep. 2016 3. doi: 10.1099

Infectious Zika viral particles in breastmilk
Dupont-Rouzeyrol M, Biron A, O’Connor O, Huguon E, Descloux E. .
Lancet. 2016 Mar 12;387(10023):1056.

Differential Susceptibilities of Aedes aegypti and Aedes albopictus from the Americas to Zika Virus
Chouin-Carneiro T, Vega-Rua A, Vazeille M, Yebakima A, Girod R, Goindin D, Dupont-Rouzeyrol M, Lourenço-de-Oliveira R, Failloux AB.
PLoS Negl Trop Dis. 2016 Mar 3;10(3):e0004543.

Whole-Genome Sequencing Analysis from the Chikungunya Virus Caribbean Outbreak Reveals Novel Evolutionary Genomic Elements.
Stapleford KA, Moratorio G, Henningsson R, Chen R, Matheus S, Enfissi A, Weissglas-Volkov D, Isakov O, Blanc H, Mounce BC, Dupont-Rouzeyrol M, Shomron N, Weaver S, Fontes M, Rousset D, Vignuzzi M.  PLoS Negl Trop Dis. 2016 Jan 25;10(1):e0004402.

Genetic Diversity and Phylogeny of Aedes aegypti, the Main Arbovirus Vector in the Pacific.
Calvez E, Guillaumot L, Millet L, Marie J, Bossin H, Rama V, Faamoe A, Kilama S, Teurlai M, Mathieu-Daudé F, Dupont-Rouzeyrol M. 
PLoS Negl Trop Dis. 2016 Jan 22;10(1):e0004374.

2015

Co-infection with Zika and Dengue Viruses in 2 Patients, New Caledonia, 2014.
Dupont-Rouzeyrol M, O’Connor O, Calvez E, Daurès M, John M, Grangeon JP, Gourinat AC.
Emerg Infect Dis. 2015. 21(2):381-2.

Detection of zika virus in urine.
Gourinat AC*, O’Connor O*, Calvez E, Goarant C, Dupont-Rouzeyrol M. 
Emerg Infect Dis. 2015. 21(1):84-6.

2014

Epidemiological and molecular features of dengue virus type-1 in New Caledonia, South Pacific, 2001-2013.
Dupont-Rouzeyrol M, Aubry M, O’Connor O, Roche C, Gourinat AC, Guigon A, Pyke A, Grangeon JP, Nilles E, Chanteau S, Aaskov J, Cao-Lormeau VM. 
Virol J. 2014. 31;11:61.

The emm-cluster typing system for group A Streptococcus identifies epidemiologic similarities across the Pacific region
Baroux N, D’Ortenzio E, Amédéo N, BakerC, Alsuwayyid BA, Dupont-Rouzeyrol M, O’Connor O, Steer A, Smeesters P.
Clin Infect Dis. 2014. 59(7):e84-92.

Isolation and partial characterization of bacteria (Pseudoalteromonas sp.) with potential antibacterial activity from a marine costal environment from New Caledonia.
Dufourcq R, Chalkiadakis E, Fauchon M, Deslandes E, Kerjean V, Chanteau S, Petit E, Guezennec J, Dupont-Rouzeyrol M. 
Lett Appl Microbiol. 2014. 58(2):102-8.

2013

Breast milk as a possible route of vertical transmission of dengue virus?
Barthel A, Gourinat AC, Cazorla C, Joubert C, Dupont-Rouzeyrol M, Descloux E. 
Clin Infect Dis. 2013 Aug;57(3):415-7.

Partial characterization of an exopolysaccharide secreted by a marine bacterium, Vibrio neocaledonicus sp. nov., from New Caledonia.
Chalkiadakis E, Dufourcq R, Schmitt S, Brandily C, Kervarec N, Coatanea D, Amir H, Loubersac L, Chanteau S, Guezennec J, Dupont-Rouzeyrol M, Simon-Colin C.
J Appl Microbiol. 2013 Jun;114(6):1702-12.

2012

Chikungunya virus and the mosquito vector Aedes aegypti in New Caledonia (South Pacific Region).
Dupont-Rouzeyrol M, Caro V, Guillaumot L, Vazeille M, D’Ortenzio E, Thiberge JM, Baroux N, Gourinat AC, Grandadam M, Failloux AB.
Vector Borne Zoonotic Dis. 2012. 12(12):1036-41.

Use of serum and blood samples on filter paper to improve the surveillance of dengue in Pacific Island Countries.
Aubry M, Roche C, Dupont-Rouzeyrol M, Aaskov J, Viallon J, Marfel M, Lalita P, Elbourne-Duituturaga S, Chanteau S, Musso D, Pavlin BI, Harrison D, Kool JL, Cao-Lormeau VM.
J Clin Virol. 2012 Sep;55(1):23-9.

Lower respiratory infections among hospitalized children in New Caledonia: a pilot study for the Pneumonia Etiology Research for Child Health project.
Mermond S, Zurawski V, D’Ortenzio E, Driscoll AJ, DeLuca AN, Deloria-Knoll M, Moïsi JC, Murdoch DR, Missotte I, Besson-Leaud L, Chevalier C, Debarnot V, Feray F, Noireterre S, Duparc B, Fresnais F, O’Connor O, Dupont-Rouzeyrol M, Levine OS. 
Clin Infect Dis. 2012 Apr;54 Suppl 2:S180-9.

2010

Aetiology of community-acquired pneumonia in hospitalized adult patients in New Caledonia.
Mermond S, Berlioz-Arthaud A, Estivals M, Baumann F, Levenes H, Martin PM.
Trop Med Int Health. 2010 Dec;15(12):1517-24.

2008

Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
Page S, Vernel-Pauillac F, O’Connor O, Bremont S, Charavay F, Courvalin P, Goarant C, Le Hello S.  Antimicrob Agents Chemother. 2008 Nov;52(11):4155-8.

Posted on

DenGen

Acronym: DenGen

logo intnetwork

 Dengue virus genotype replacements : investigating viral fitness differences driving the evolution of dengue epidemics 
Principal investigator M. Dupont-Rouzeyrol
IPNC main investigator O. O’Connor / M. Dupont-Rouzeyrol
IPNC collaborators N. Pocquet
Other collaborators L. Lambrechts (IP), V. Duong (IPC), P. Dussart (IPC)
Project total budget 50 000 € Budget devoted to IPNC: 21 200 €
Financial supports Actions Concertées Inter Pasteuriennes (ACIP)
Timeline Start date: Jan 2017 End date: December 2018
Context
Phylogenetic analyses have revealed that dengue virus (DENV) evolutionary dynamics are often characterized by the replacement of a DENV genotype by another genotype of the same serotype. Such genotype replacements are epidemiologically significant because they can be associated with changes in disease severity and human immunity. However, the mechanisms underlying DENV genotype turnover in nature remain poorly defined.
Objectives
The specific objectives of this study, led in two different epidemiological contexts: a hyper-endemic area: Cambodia, and an epidemic area: New Caledonia (NC), are: ii) By focusing on vector-virus interactions in vivo, to study the potential role of vector-driven selection in DENV genotype replacements; iii) By focusing on DENV replication kinetics in mammalian cells in vitro, to study the relative ability of DENV genotypes to replicate and produce subgenomic flavivirus (sf) RNAs.
Methods
DENV evolutionary dynamics in NC and Cambodia: About 20 strains per year since 2009 will be selected. E-gene will be sequenced in order to determine the genotype belonging. Based on these results, five representative strains by serotype/genotype will be selected for whole genome sequencing.

DENV competitive fitness in vivo by vector competence assays: Two DENV strains per genotype will be selected for competitive experiment. F1 or F2 generation of Ae. aegypti will be challenged with different ratios of both DENV strains. Infection, dissemination and transmission rates will be measured at day 7 and 14 post-exposure. Virus quantification of both genotype will be performed by RT-qPCR.

DENV replicative fitness in vitro: Replication kinetics of representative DENV strains and production of sfRNA will be observed over 5 days on mammalian cells. RNA quantification will be performed as previously.
Results
All the DENV strains (NC and Cambodia) were obtained after not more than three passages on C6/36 cells. All of them were send to IP for high-throughput sequencing of the whole genome. This one is in progress. Vector competence experiments and in vitro studies are scheduled for the first semester of 2018.
Perspectives
This project will allow us to better understand the evolutionary mechanisms driving DENV genotype shifts typically observed during the course of dengue epidemics.

Acronym: DenGen

logo intnetwork

 Dengue virus genotype replacements : investigating viral fitness differences driving the evolution of dengue epidemics 
Principal investigator M. Dupont-Rouzeyrol
IPNC main investigator O. O’Connor / M. Dupont-Rouzeyrol
IPNC collaborators N. Pocquet
Other collaborators L. Lambrechts (IP), V. Duong (IPC), P. Dussart (IPC)
Project total budget 50 000 € Budget devoted to IPNC: 21 200 €
Financial supports Actions Concertées Inter Pasteuriennes (ACIP)
Timeline Start date: Jan 2017 End date: December 2018
Context
Phylogenetic analyses have revealed that dengue virus (DENV) evolutionary dynamics are often characterized by the replacement of a DENV genotype by another genotype of the same serotype. Such genotype replacements are epidemiologically significant because they can be associated with changes in disease severity and human immunity. However, the mechanisms underlying DENV genotype turnover in nature remain poorly defined. Des analyses phylogénétiques ont révélé que la dynamique évolutive du virus de la dengue (DENV) est souvent caractérisée par le remplacement d’un génotype du DENV par un autre génotype du même sérotype. De tels remplacements génotypiques sont épidémiologiquement significatifs car ils peuvent être associés à des modifications de la sévérité de la maladie et de l’immunité humaine. Cependant, les mécanismes sous-jacents à ce renouvellement du génotype de DENV dans la nature restent mal définis.
Objectives
The specific objectives of this study, led in two different epidemiological contexts: a hyper-endemic area: Cambodia, and an epidemic area: New Caledonia (NC), are: ii) By focusing on vector-virus interactions in vivo, to study the potential role of vector-driven selection in DENV genotype replacements; iii) By focusing on DENV replication kinetics in mammalian cells in vitro, to study the relative ability of DENV genotypes to replicate and produce subgenomic flavivirus (sf) RNAs. Les objectifs spécifiques de cette étude, menée dans deux contextes épidémiologiques différents: une zone hyper-endémique: Cambodge, et une zone épidémique: Nouvelle-Calédonie (NC), sont : i) étudier in vivo le rôle potentiel de la sélection dirigée par le vecteur dans les remplacements génotypiques du DENV ; ii) étudier in vitro la capacité relative des génotypes du DENV à se répliquer et à produire des ARN subgénomiques du flavivirus.
Methods
DENV evolutionary dynamics in NC and Cambodia: About 20 strains per year since 2009 will be selected. E-gene will be sequenced in order to determine the genotype belonging. Based on these results, five representative strains by serotype/genotype will be selected for whole genome sequencing.

DENV competitive fitness in vivo by vector competence assays: Two DENV strains per genotype will be selected for competitive experiment. F1 or F2 generation of Ae. aegypti will be challenged with different ratios of both DENV strains. Infection, dissemination and transmission rates will be measured at day 7 and 14 post-exposure. Virus quantification of both genotype will be performed by RT-qPCR.

DENV replicative fitness in vitro: Replication kinetics of representative DENV strains and production of sfRNA will be observed over 5 days on mammalian cells. RNA quantification will be performed as previously.

 Dynamique évolutive du DENV en NC et au Cambodge: environ 20 souches par an depuis 2009 seront sélectionnées. Le gène E sera séquencé afin de déterminer l’appartenance du génotype. Sur la base de ces résultats, cinq souches représentatives par sérotype / génotype seront sélectionnées pour le séquençage du génome entier.

Fitness compétitive du DENV in vivo par des analyses de compétence vectorielle: Deux souches de DENV par génotype seront sélectionnées pour l’expérience de compétition. Une génération F1 ou F2 d’Ae. aegypti sera mise en contact avec différents ratios des deux souches du DENV. Les taux d’infection, de dissémination et de transmission seront mesurés aux jours 7 et 14 après l’exposition. La quantification virale des deux génotypes sera effectuée par RT-qPCR.

Fitness réplicatif du DENV in vitro: La cinétique de réplication de souches représentatives du DENV et la production de sfRNA seront observées pendant 5 jours sur des cellules de mammifères. La quantification de l’ARN sera effectuée comme précédemment.
Results
All the DENV strains (NC and Cambodia) were obtained after not more than three passages on C6/36 cells. All of them were send to IP for high-throughput sequencing of the whole genome. This one is in progress. Vector competence experiments and in vitro studies are scheduled for the first semester of 2018. Toutes les souches du DENV (NC et Cambodge) ont été obtenues après moins de trois passages sur des cellules C6/36. Elles ont toutes été envoyées à l’IP pour le séquençage à haut débit du génome complet. Celui-ci est en cours de réalisation.
Perspectives
This project will allow us to better understand the evolutionary mechanisms driving DENV genotype shifts typically observed during the course of dengue epidemics. Ce projet nous permettra de mieux comprendre les mécanismes évolutifs qui sous-tendent les remplacements de génotypes du DENV typiquement observés au cours des épidémies de dengue.
Posted on

DenVect

Acronym: DenVect Vector competence of Aedes aegypti for Dengue viruses in New Caledonia
Principal investigator: O. O’Connor
IPNC main investigator: O. O’Connor, M. Dupont-Rouzeyrol
IPNC collaborators: C. Inizan, N. Pocquet
 Budget 8380 € Budget devoted to IPNC:
Financial supports IPNC
Timeline Start date: Aug.2016 End date: July 2017
Context
Occurence of dengue outbreaks needs three key actors: the pathogen (i.e. the virus), the vector (Aedes sp.) and the human host. In New Caledonia, Ae. aegypti is the major (the only proven to date) vector of arboviruses. Since World War II, NC was regularly affected by dengue outbreaks with a cycling circulation of the four DENV serotypes. However, by the beginning of the year 2000, this pattern has changed with the persistence of DENV-1. These observations suggest that our local vector is competent for DENV. However, its capability to be infected by DENV, allowing the replication and transmission of the virus to human host, has not been studied yet.
Objectives
We propose to investigate the ability of New Caledonian Ae. aegypti population to transmit different DENV serotypes, in link with the epidemiological profile observed.
Methods

Selection of DENV strains from viro-bank and virus stock production: one representative DENV strain of each serotype/genotype will be selected in IPNC viro-bank depending on the year of epidemic circulation. The selected strains will be amplified on C6/36 cells with no more than three passages. Quantification of viruses obtained will be performed by immunofluorescent focus assay on C6/36 cells.

Phenotypic characterization of representative strains in the vector: An Ae. aegypti F1 generation will be used for vector competence studies carrying out on each representative DENV strains. Two independent experiments will be performed, each with the four DENV serotype strains. Infection, dissemination and transmission rates will be measured at day 7 and 14 post-exposure. Samples analysis will be performed as previously described.
Results
DENV-1 to -4 strains, phylogenetically characterized, were obtained on C6/36 cells. The two independent vector competence experiments were conducted with all DENV strains. Preliminary results obtained from the first experiment show that New Caledonian Ae. aegypti are capable to transmit DENV.  Transmission of DENV-1 (genotype I “Asian”) and DENV-4 is observed as early as 7 days post-exposure with rates of 20% and 33% respectively. At 14 days post-exposure, the transmission efficiency is varying from 12.5% to 22% for all the DENV strains. Analysis of the second experiment is in progress.
Perspectives
In New Caledonia, the context is particularly favourable to study the dynamic of DENV transmission, as Ae.  aegypti is the only proven arboviruses vector and the epidemiology of dengue is well-kown. Thus, this project will allow us to have a global vision of the Ae. aegypti competence at a given time, which is an important point to better understand the transmission and dynamics of DENV in New Caledonia.
Posted on

Dengue severity

2017 Dengue outbreak, Investigations of severe cases : Dengue Severity
Principal investigator M. Dupont-Rouzeyrol
IPNC main investigator M. Dupont-Rouzeyrol
IPNC collaborators A. Tarantola, C. Inizan, M. Minier, O. O’Connor
Other collaborators E. Simon-Lorière, A. Sakuntabhai (IPP), E. Descloux, M. Sérié, M.-A. Goujart,, A.-C. Gourinat (CHT), C. Forfait, A. Pfannstiel (DASS-NC).
Budget Budget devoted to IPNC 
Financial supports IPNC, IPP, CHT, NC
Timeline Start date: Sept.2017 End date : Sept. 2018
Context
With 4,401 dengue cases (2,548 biologically confirmed), 579 hospitalized cases and 11 deaths between Jan 1st and Oct 8th 2017, the 2016-2017 dengue epidemic in New Caledonia (NC) was sizeable. More importantly, it was associated with a higher percentage of hospital admissions and severe clinical presentations (liver injury, ophthalmic complications…). The higher occurrence of deaths and heretofore rare hepatic forms observed during this epidemic may be linked with specific characteristics of viruses, patients, or host-pathogen response.
Objectives
To determine whether severe presentations of dengue infections were associated with specific characteristics such as virus genotype and hepatic tropism, patient comorbidities or earlier infection by dengue or Zika viruses.
Methods
Patients already included in the ArboVirtuess study will be asked to continue their participation and contribute an additional blood sample.

– Selection of 50 sera from 2017 and previous years available for analysis: 1/3 severe forms versus 2/3 non-severe

– Phylodynamic studies based on whole-genome sequencing. Search for variations in viral quasi-species.

– Comparative analysis of the hepatic tropism of viral strains representative of 2016-2017 epidemic versus previous years

– Sera characterization: history of previous arbovirus infections, impact of pre-existing humoral immunity on DENV replication in human monocytes (ADE)
Preliminary results
Ethical approval for patient recall have been obtained and sera have been selected and collected. Viral RNAs have been extracted from the sera and whole-genome sequencing is in progress. In parallel, viruses from this year’s epidemic are currently being isolated on mosquito C6/36 cells and will be titrated. Experimental conditions for human hepatic cell line infection as well as for ADE have been set up and are currently being validated. Characterization of viruses’ hepatic tropism and sera inhibition/enhancement capacity will soon be initiated.
Perspectives
First, this study may shed light on a potential evolution of viruses involved in severe cases compared to non-severe dengue cases, in link with a modification in virus hepatic tropism. Second, this project will provide an unprecedented characterization of the impact of anti-Zika antibodies on DENV infection. Overall, this study is expected to further the understanding of the unusual severity of DENV epidemic in 2017. Such documentation of the influence of a pre-existing anti-Zika humoral immunity on dengue severity would be useful for territories displaying an epidemiological situation similar to NC, thus suggesting a new indicator to estimate the risk of progression towards severe dengue.
Posted on

VIP

Acronym: VIP Are dengue Defective Interfering Particles truly interfering?
Principal investigator C. Inizan
IPNC focal point C. Inizan / M. Dupont-Rouzeyrol
IPNC collaborators O. O’Connor
Other collaborators
Project total budget 8 275 € Budget devoted to IPNC  NA
Financial support IPNC
Timeline Start: March 2017 End: Feb. 2018
Context
Polymerase errors occurring upon viral replication might give rise to incomplete genomes that are nevertheless encapsidated in Defective Viral Particles (DVP). Replicated and maintained upon co-infection with functional viruses, such DVPs might affect the physiopathology of the infection: inhibition of viral replication, modulation of the host immune response as well as contribution to infection persistence. In the case of dengue virus (DENV), DVPs have been detected in both humans and Aedes mosquitoes. They might represent a natural regulator of viremia in patients, thus impacting infection evolution and resolution.
Objectives
The current study aims at evaluating DVP role in viremia regulation in patients. This project includes (i) the characterization and quantification of DVPs in the sera of dengue patients, in link with viremia and, (ii) the measure of DVP impact on DENV replication in vitro.
Methods
Molecular characterization of DVPs in the sera of dengue patients from New Caledonia:

– Evaluation of patients viremia through in vitro infections and real-time RT-PCT

– Quantification and analysis of DVPs subgenomic RNA profiles in patients’ sera through real-time RT-PCR

– Sequencing of DVPd subgenomic RNAs in patients sera

Measure of the modulation of DENV replication in vitro by DVPs:

– Production and purification of DVPs through in vitro infections and ultracentrifugation

– Quantification of DVP impact on DENV replication in human cells in vitro through real-time RT-PCR
Preliminary results
Viral infectious titers of 50 sera of patients from New Caledonia infected by DENV-1 genotype I have been evaluated through in vitro infections. In parallel, viral RNAs have been extracted from those sera. Molecular analyses are being set up and will soon enable the quantification and sequencing of DVPs subgenomic RNAs.
Perspectives
Through the implementation of DVPs detection and purification tools, the current project opens new avenues for a broader study on DVPs role in DENV natural cycle, aiming at measuring their impact on dengue physiopathology and transmission. This study of the impact of DVPs on viremia might suggest their quantification in patients’ sera as a prognostic tool for infection severity.
Posted on

R-Zero

Acronym : R-Zero Risk factors for Zika virus Emergence and Recurrent Outbreaks within the Pacific area.
Principal investigator VM. Cao-Lormeau (ILM)
IPNC main investigator M. Dupont-Rouzeyrol
IPNC collaborators D. Girault, A. Tarantola
Other collaborators Ministère de la santé de Fidji, Samoa et Yap, Institut Pasteur, London School of Hygiene and Tropical Medicine, Queensland University of Technology
Project total budget 32 000€
(phase 1)		 Budget devoted to l’IPNC  3 000 €
Financial supports Pacific Funds (phase 1/3)
Timeline Start date: Jul 2017 End date: July 2018
Context
In 2014, Zika (ZIKV) emerged in the Pacific region and spread in the world. In early 2016, WHO declared the ZIKV outbreak an international public health emergency in connection with the severe neurological consequences observed following ZIKV infection. Since then, the number of countries reporting a Zika epidemic has steadily increased, illustrating that ZIKV’s geographic expansion is still ongoing, even in the region. In addition, the reappearance of ZIKV in the Federated States of Micronesia, Kosrea, 8 years after the Yap epidemic, illustrates the risk of outbreak’s recurrence in previously exposed areas.
Objectives
The overall objective of this project is to identify the risk factors for the emergence and recurrence of Zika epidemics in the Pacific, with a particular focus on anti-Zika community immunity.
Methods
Characterization of the memory immune response against ZIKV – persistence and possible interference with dengue

Community mmunity against ZIKV – Status and Evolution in 4 Pacific sites

Epidemic dynamics of Zika – risk factors for epidemic emergence and recurrence
Perspectives
This project is expected to gather crucial information on the persistence of protective immunity against Zika virus in infected patients. It should also be used to assess the level of exposure and immunity of Pacific populations to the Zika virus.
Valorisation 
Communication : M. Dupont-Rouzeyrol, R-Zero Workshop, Tahiti, 2017 (Oral)